Study Overview
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Study Overview
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
BGB-A317-302
Active, not recruiting
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Beigene Study ID
BGB-A317-302
ClinicalTrials.gov ID
EudraCT Number
2017-003699-30
Clinical Drug Trials ID
CTR20171026
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents